David Khayat

David Khayat: The Doctor Who Declared War on Cancer

He was eighteen when his best friend's bride was given a terminal diagnosis and then, improbably, recovered — treated by Jean Bernard, the towering French haematologist of the postwar era. Watching a death sentence get overturned, David Khayat concluded he was witnessing "the beginning of a scientific revolution" and decided to join it. Four decades later he had built France's national cancer institute, written its first war plan against the disease, and become one of the most recognisable physicians in the country — before a newspaper investigation attached his name to the tobacco industry.

From Tunis to Nice

Khayat was born on 27 August 1956 in Tunisia, into a family of modest means, and came to France at the age of four. He entered medicine at the University of Nice in 1974 and finished there in 1980, then moved into the ferociously competitive Paris hospital system for internship and residency. He won a place in oncology by concours and, rather than proceed straight into practice, deferred his military service to do laboratory research — the first sign of a career that would keep refusing the obvious next step.

The Receptor Nobody Believed

That research took him to Israel, to work under Professor Isaac Witz at Tel Aviv University on tumour immunology. There he found something that should not have been there: a soluble Fc receptor circulating in mouse serum. Fc receptors were understood to sit on cell membranes; a free-floating version looked to most reviewers like a laboratory artefact, and it was dismissed as such. Khayat's response was to replicate the result until it could not be waved away. The persistence attracted attention at Mount Sinai School of Medicine in New York, where he went on to identify the same soluble receptor in human serum. The work became his 1988 doctorate in tumour immunology at the University Pierre and Marie Curie, on the identification and purification of soluble Fc receptors in human and mouse sera, taken alongside his MD and oncology board certification in 1985.

Building a Discipline

He returned to Pitié-Salpêtrière as an assistant professor in 1985, became a full professor at Pierre and Marie Curie in 1989, and took over as Head of Medical Oncology at Pitié-Salpêtrière in 1990 — a post he would hold for decades. His laboratory and clinical output ran past 500 peer-reviewed publications, spanning tumour immunology, the pharmacokinetics of anti-cancer drugs, and the problem of predicting which melanoma patients respond to immunotherapy. He ran phase I and phase II trials in breast, colorectal and lung cancer and melanoma, the unglamorous early-stage work where most new drugs quietly die.

Structural ambition came with it. In 1998 he founded the French Federation of Medical Oncologists and served as its first president until 2001, giving a profession that had been scattered across specialties a single voice. He created a Master of Excellence in Medicine in Oncology to train the next French cohort, and accumulated appointments abroad — an adjunct professorship at MD Anderson Cancer Center in Houston, emeritus chairs in China and Japan.

Chirac's War

The turn from clinician to architect came in 1999, when Khayat and the American oncologist Gabriel Hortobagyi drafted the Charter of Paris Against Cancer, built on a proposition that sounds anodyne and was not: that cancer patients' rights are human rights. The charter was signed by President Jacques Chirac and endorsed by UNESCO's director-general Koïchiro Matsuura, and the two men organised the World Summit Against Cancer around it in 2000 and 2001.

Chirac decided his presidential legacy would be a war on cancer, and in July 2002 he recruited Khayat to write it. The resulting Plan cancer was a national mobilisation — screening, treatment standards, research funding and patient rights bound into a single programme with political authority behind it. Its institutional monument was the Institut National du Cancer, created to give France a permanent command centre for the disease. Khayat was appointed founding president in April 2004, served until September 2006, and stayed on as honorary president. He also founded and led the Foundation AVEC, declared of public utility in 2013 and dissolved in 2020, which funded research and patient quality-of-life programmes.

The recognitions accumulated: the American Association for Cancer Research public service award in 2000, a Bristol Myers Squibb Foundation research grant the same year, chevalier of both the Légion d'honneur and the Ordre national du Mérite, an honorary CBE from Britain, Senegal's Order of the Lion, and Russia's Order of Friendship.

The Public Doctor

Khayat became, unusually for a research oncologist, a household name in France. He wrote bestsellers, including medical thrillers and a widely read book on diet and cancer, and made a point of confining the writing to holidays, planes and trains so it would not intrude on the hospital. It was a carefully managed public persona: the professor who could explain oncology on television without condescension, and who insisted that prevention and pleasure at the table were not opposites.

The Philip Morris Files

In April 2021 that persona took serious damage. An investigation by *Le Monde* journalists Stéphane Horel and Jérémie Baruch reported that Khayat had, during the 2010s, built a consulting practice with industry on "risk reduction" — and that the clients included Philip Morris International, for whom the reporting described lobbying activity favourable to heated tobacco products in France and in Hong Kong. The charge was not illegality but incongruity: the man who had written France's war plan against cancer had been paid by the industry that causes most of it. It is the single fact that any honest account of his career must carry alongside the rest.

Why David Is Called a Genius

The claim rests on a combination rather than a single discovery. As a scientist, Khayat had the rarest useful quality — refusal to accept a convenient dismissal. When his soluble Fc receptor in mouse serum was called an artefact, the standard move was to drop it; he replicated it until it held, then found it in humans, turning a rejected observation into a doctorate. That is less raw brilliance than calibrated stubbornness, which in laboratory science is frequently the same thing.

The larger claim is organisational. His real originality was seeing that the bottleneck in French cancer outcomes was not molecular but architectural — that a country could have excellent oncologists and still lose patients because screening, standards, funding and research sat in separate silos with nobody in charge. The Charter of Paris, the Plan cancer, INCa and the Federation of Medical Oncologists are versions of one insight: build the institution, and the medicine follows. Few clinicians can hold a phase I protocol and a national health architecture in mind at once.

The counter-case has two parts and both are fair. None of this is discovery in the sense the word usually implies: there is no Khayat mechanism, no eponymous drug, no theory that changed what oncologists believe. He was an outstanding builder and communicator inside a field others transformed. And the *Le Monde* reporting on his Philip Morris consulting cuts at the credibility that made the institutional work possible. Judgement, not only intellect, is part of what the word is supposed to certify.

Legacy

The Institut National du Cancer still stands, and the framework Khayat drafted for Chirac remains the spine of how France organises itself against the disease — the most consequential thing he made, and the one least attached to his name in public memory. Hundreds of French oncologists passed through his department or his training programme. His reputation is now permanently double-exposed: the physician who told a nation cancer was winnable, and the consultant whose invoices came from the other side.

Achievements

• Knight of the Legion of Honour
• Knight of the National Order of Merit
• Knight of the French Order of Academic Palms
• Officer of the Legion of Honour — 2006
• Held posts at The University of Texas MD Anderson Cancer Center and Philip Morris International